Eurasia Journal of Science and Technology
ISSN: 2663-1016
DOI: 10.61784/ejst3030

APPLICATION OF STATISTICS IN THE APPLICATION OF CELL THERAPY RESEARCH

RongMing Zhou
JIU ZHI TANG MAKER (Beijing) Cell Technology Co., Ltd, Beijing 102600, China.
Corresponding Email: nicetomeetyouhere@163.com

Abstract: This article explores the application of statistics in cell therapy research, especially in the fields of immunotherapy and neural repair. The article emphasizes the key role of statistical methods in evaluating treatment effects, managing risks, and designing rational clinical trials. Through tools such as survival analysis, hypothesis testing, and statistical models, researchers can intuitively assess patients' survival and progression-free survival, as well as predict treatment effects and adverse reactions. The article also discusses the challenges of randomized controlled trial design, multicenter studies, and the importance of data management and analysis. Finally, the article points out the value and prospects of statistics in cell therapy research, while also proposing the limitations of current research and future directions.
Keywords: Cell therapy; Statistical application; Survival analysis; Hypothesis testing; Randomized controlled trial

1 INTRODUCTION

1.1 Research Background

Cell therapy is an important breakthrough in modern biomedical, especially in the fields of immunotherapy and nerve repair. The chimeric antigen receptor T cell (Car-T) therapy and stem cell therapy represent the two mainstream directions of cell therapy, especially when treating complex diseases such as cancer and nervous system diseases. However, with the deepening of research, the clinical transformation of cell therapy faces many challenges, including the uncertainty of the curative effect, the complexity of the treatment standards, and the management of adverse reactions [1].
Statistical methods provide important support for solving these problems. Through accurate data analysis, statistical help researchers evaluate the efficacy, management risks, and design more reasonable clinical trials. This not only improves the scientific and repeatability of research, but also promotes the smooth transition from laboratory to the clinical transition from laboratory.

1.2 Research Objectives

This review aims to explore the application of statistics in cell therapy research, focusing on the critical role of statistical methods in various phases of cell therapy. By reviewing current literature, this paper will introduce the application of common statistical tools such as survival analysis, hypothesis testing, and statistical models in cell therapy, evaluating their contributions to clinical trial design, efficacy assessment, and data management, thereby providing a reference for future cell therapy research.

2 STATISTICAL APPLICATIONS IN CELL THERAPY

2.1 Survival Analysis

In cell therapy research, survival analysis is a crucial statistical method primarily used to evaluate patient survival and progression-free survival (PFS) after treatment[2]. The Kaplan-Meier curve is a common tool that intuitively displays the survival outcomes of patients in different treatment groups by plotting cumulative probability curves of survival time. For example, in studies of chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory multiple myeloma, the Kaplan-Meier curve is used to assess overall survival (OS) and progression-free survival after CAR-T cell treatment[3]. Through this method of analysis, researchers can intuitively understand the survival differences among various patient groups after treatment.
In addition, the Cox proportional hazards regression model is often applied in survival analysis to evaluate the impact of various factors, such as age, baseline health status, and CAR-T cell expansion, on patient survival time. Through this model, researchers can analyze which factors are significantly associated with long-term survival in cell therapy, providing important references for the development of personalized treatment plans [4].

2.2 Hypothesis Testing

Hypothesis testing is widely applied in evaluating the efficacy of cell therapy, particularly when comparing the efficacy differences of various treatment regimens. Common hypothesis testing methods include the T-test and the Chi-square

test. The T-test is primarily used for comparing intergroup differences of continuous variables (such as blood indicators or cell counts), while the Chi-square test is used for comparing differences in categorical variables (such as the rate of efficacy achievement) [5].

In cell therapy research, researchers often use the T-test to assess changes in biomarkers in patients' blood before and after treatment, such as changes in the concentration of inflammatory factors (IL-6, TNF-α). Through these statistical tests, researchers can determine whether the treatment significantly improved the physiological state of patients. Additionally, the Chi-square test is frequently used to analyze the proportions of patients achieving complete or partial remission after receiving cell therapy, thereby evaluating the efficacy differences of different treatment methods [6].

2.3 Statistical Models

Statistical models play a vital role in cell therapy research, especially in efficacy prediction and risk assessment. Linear regression and logistic regression are the most commonly used statistical models for analyzing the multidimensional influencing factors of cell therapy efficacy [7]. The linear regression model is used to analyze the relationship between continuous variables, while the logistic regression model is widely applied to analyze categorical outcomes, such as whether patients experience adverse reactions or whether the treatment meets the target.

In CAR-T therapy, logistic regression models are used to predict whether patients will experience severe adverse reactions such as cytokine release syndrome (CRS). Researchers construct risk models by analyzing patients' baseline characteristics and cell levels before and after treatment to help predict and intervene in potential severe adverse reactions in advance. The application of these models enhances the safety of treatment and helps optimize treatment strategies.

3 CLINICAL TRIAL DESIGN IN STATISTICS

3.1 Randomized Controlled Trial Design

Randomized controlled trials (RCTs) are considered the "gold standard" for evaluating efficacy in cell therapy research. Through RCTs, researchers can randomly assign patients to either a treatment group or a control group, avoiding potential biases and ensuring a scientific assessment of treatment effects. RCTs have been widely applied in CAR-T cell therapy and neural repair treatments [8]. For example, in studies of CAR-T therapy for relapsed multiple myeloma, patients are assigned to different treatment groups through a rigorous randomization process, and the progression-free survival (PFS) and overall survival (OS) of patients are evaluated using statistical tools such as Kaplan-Meier survival curves. However, despite being the main tool for efficacy assessment, RCTs in cell therapy often face numerous challenges. First, cell therapy involves complex individual patient differences, making standardized treatment difficult. Second, adverse reactions in cell therapy, such as cytokine release syndrome (CRS), have not been fully understood in terms of their impact on treatment effectiveness and patient safety, adding to the complexity of RCTs [9].

3.2 Challenges of Multi-Center Studies

Multi-center clinical trials are an important means for validating the effects of cell therapy. Particularly in neural repair and CAR-T treatment research, more trials are spanning multiple research centers to increase sample size and improve the generalizability of results. However, multi-center studies also face some unique statistical challenges. Due to significant variations in data collection and processing methods between different centers, there may be heterogeneity in study outcomes. To reduce this heterogeneity, researchers often use stratified randomization in the trial design to ensure balanced patient distribution across centers [10]. Additionally, data integration and analysis often require advanced statistical methods.If broad generalized linear mixed models (GLMM) are used to address systemic differences between various centers[11].

Additionally, the complexity of cell therapy further exacerbates the challenges of multi-center trials. There is significant variation in patient responses to treatment, and rigorous quality control of cell products and standardization of therapeutic procedures are required. Even within the same research center, different cell therapy protocols or experimental designs can significantly impact the outcomes. Therefore, in multi-center research, researchers need to ensure the rigor of trial design and utilize effective statistical analysis tools to handle complex heterogeneity[12].

4 CASE STUDIES IN STATISTICAL ANALYSIS

4.1 Statistical Analysis of CAR-T Therapy

Chimeric Antigen Receptor T-cell (CAR-T) therapy is one of the cutting-edge technologies in cellular immunotherapy, especially showing remarkable efficacy in treating hematological malignancies such as acute B-lymphoblastic leukemia (B-ALL) and multiple myeloma. In these studies, statistical methods play a crucial role in efficacy evaluation and adverse reaction monitoring.

In BCMA-targeted CAR-T therapy research, Kaplan-Meier survival curves are used to evaluate patients' progression-free survival (PFS) and overall survival (OS), revealing differences in survival rates among patients in different treatment groups through survival analysis[13]. Additionally, the Cox proportional hazards model is employed

to analyze the relationship between patients' baseline indicators, changes in cytokines pre- and post-treatment, and efficacy. For example, studies indicate a positive correlation between the expansion of CAR-T cells in peripheral blood and patient efficacy.

Moreover, adverse reactions in CAR-T therapy, such as Cytokine Release Syndrome (CRS), are predicted using statistical models. Researchers use logistic regression models to evaluate the impact of baseline data on the incidence of adverse reactions.

To identify factors significantly associated with CRS risk through multivariate analysis, which helps optimize treatment plans and improve safety.

4.2 Statistical Applications in Neurological Treatments

In cell therapy for neurological diseases, cell types like mesenchymal stem cells and olfactory ensheathing cells are widely used for the repair of neural injuries. Statistical methods are applied to evaluate the efficacy and safety of these treatments [14]. For instance, in studies of neurological disorders such as spinal cord injuries and stroke sequelae, Kaplan-Meier curves are used to analyze the recovery of neural functions in patients, while Cox regression models are employed to assess multiple factors affecting treatment outcomes, including cell type, dosage, and disease duration [15].

Although some studies show the potential of cell therapy in neurological diseases, some multicenter randomized controlled trials (RCTs) have failed to demonstrate significant efficacy. For example, certain stem cell therapies have shown improvement in neural functions in small sample studies but did not significantly improve quality of life or neural functions in large multicenter studies. This suggests that further optimization of treatment plans and standardization of treatment processes may be key to enhancing efficacy [16].

5 DATA MANAGEMENT AND ANALYSIS

5.1 The Importance of Data Collection

In the research of cell therapy, data collection is a crucial aspect that determines the success of clinical trials. Scientific and systematic data collection and management ensure more accurate evaluation of treatment efficacy and help in timely detection of adverse reactions [17]. For complex therapies like CAR-T, researchers need to comprehensively collect diverse information such as patients' baseline data, cell expansion during treatment, and immune responses. This data not only aids researchers in evaluating short-term efficacy but also provides essential insights for analyzing long-term efficacy and survival rates [18].

Modern data collection tools, such as Electronic Data Capture (EDC) systems, have greatly improved the accuracy and completeness of data. Furthermore, data collection in multicenter studies requires special attention to standardization. Different centers may have varying data collection methods, and it is crucial to ensure that standards and data formats are consistent across all centers to facilitate subsequent data integration and analysis [19].

5.2 Data Modeling and Analysis

Data modeling is a critical step in the analysis of cell therapy data, helping researchers extract valuable information from complex clinical data. Common modeling methods include linear regression, logistic regression, and survival analysis models. Through these statistical models, researchers can predict patients' treatment responses, efficacy, and potential adverse reactions.

In CAR-T therapy, data modeling is used not only for efficacy prediction but also for assessing treatment safety. For example, researchers use logistic regression models to predict which patients have a higher risk of cytokine release syndrome (CRS) and intervene early to reduce the treatment risk. In the context of cell therapy for neurological diseases, data modeling is also used to analyze the relationships between different cell types, doses, and efficacy, helping to optimize treatment plans [20].

6 CONCLUSION

6.1 The Value and Prospects of Statistics

Statistics hold critical value in cell therapy research. Through survival analysis, hypothesis testing, and statistical models, researchers can accurately evaluate the efficacy of cell therapies, optimize clinical trial design, and improve treatment safety [21]. For instance, Kaplan-Meier curves provide an intuitive illustration of progression-free survival and overall survival, aiding researchers in quickly identifying differences between treatment groups.

In addition, statistical tools such as Cox regression models are also used to analyze the impact of multiple factors on treatment outcomes, providing theoretical support for personalized therapy. As the application of cell therapy continues to expand, such as CAR-T cell therapy and neural repair therapy, the role of statistics will become more widespread [22]. In the future, combining machine learning and big data technologies, statistics will further enhance data processing capabilities in cell therapy, thereby promoting improvement in treatment effectiveness and ensuring safety.

6.2 Limitations and Prospects of the Study

Although statistics provide strong support for cell therapy research, some challenges remain. First, different statistical models are suitable for different types of research, and inappropriate model selection may lead to errors. Second, in multi-center studies, the issue of data heterogeneity between different centers is still a major challenge, requiring more flexible statistical models to solve [23].

Future research should further optimize the application of statistics in cell therapy, especially in adverse reaction prediction and data integration. Additionally, researchers should also focus on how to use emerging statistical techniques and tools to handle increasingly complex clinical data to improve the efficiency and efficacy of cell therapy [24].

By continuing to advance high-quality randomized controlled trials and more precise statistical analyses, statistics will provide stronger support for the future development of cell therapy.

COMPETING INTERESTS

The authors have no relevant financial or non-financial interests to disclose.

REFERENCES

[1] Zu Cheng, Wang Kexin, Zhang Qiqi, et al. Clinical observation of BCMA-targeted chimeric antigen receptor T cell therapy for relapsed/refractory multiple myeloma with hemophagocytic syndrome. Journal of Zhejiang University (Medical Edition), 2022, 51(02):160-166.

[2] Chen Y, Jian T, Shen Y. Immune Checkpoint Inhibitors in Lung Cancer// Wuhan Zhicheng Times Cultural Development Co., Ltd.. Proceedings of 2nd International Conference on Biomedical Engineering, Healthcare and Disease Prevention (BEHDP 2022). Capital Medical University; Guizhou Medical University; Shenzhen College of International Education, 2023: 10.

[3] Guo Huanxu, Fan Dan, Zhang Jingyi, et al. Comparative efficacy of first-line immunosuppression and hematopoietic stem cell transplantation in treating hepatitis-associated aplastic anemia. Journal of Clinical Hematology, 2024, 37(05): 343-348.

[4] Wang Hongjuan, Hu Wen, Ding Yuan, et al. Meta-analysis of efficacy of autologous cell transplantation in the treatment of stable vitiligo. Chinese Journal of Dermatovenerology of Integrated Traditional and Western Medicine, 2024, 23(01): 22-29.

[5] Liu Yukai, Liu Qi, Ma Cong, et al. Effect of anti-CD19 chimeric antigen receptor T-cell therapy on pediatric acute B-lymphoblastic leukemia. Chinese Medical Innovation, 2023, 20(16): 43-47.

[6] Zhang Zhanqiang, Zhang Gailing, Li Wenqian, et al. Relationship between platelet count and the efficacy of CD19-CAR-T cell therapy in refractory/relapsed acute B lymphoblastic leukemia. Journal of Clinical Hematology, 2022, 35(09): 674-676+679.

[7] Huang Hongyun, Chen Lin, Mao Gengsheng, et al. Progress in clinical cell therapy in neurorestoratology. Chinese Journal of Cellular and Stem Cell Research (Electronic Edition), 2022, 12(01): 1-7.

[8] Wu Qiaozhu, Tian Chunfang. Research progress in the treatment of intrauterine adhesion. Guide to Women and Children's Health, 2024, 3(18): 23-26+30.

[9] Guo X, Sheng X. Drug discovery of PD-L1 inhibitor Atezolizumab// Wuhan Zhicheng Times Cultural Development Co., Ltd.. Proceedings of 2nd International Conference on Biomedical Engineering, Healthcare and Disease Prevention (BEHDP 2022). The university of Strathclyde;The University of Melbourne, 2023: 8.

[10] Xu Xiaoming, Xia Yunlong, Xia Linying, et al. Advances in Non-Pharmacological Treatment of Heart Failure with Preserved Ejection Fraction. Chinese Journal of Interventional Cardiology, 2024, 32 (09): 528-534.

[11] Zhang Weijie, Zhang Hong. Research Progress on the Relationship between Iron Deficiency and Heart Failure. Journal of Cardiovascular and Cerebrovascular Diseases with Integrated Traditional and Western Medicine, 2024, 22 (18): 3343-3346.

[12] Li Zhe, Guo Guangling, Li Ping, et al. Network Meta-Analysis of the Efficacy of Mesenchymal Stem Cells from Different Sources in the Treatment of Animal Models of Premature Ovarian Failure. Chinese Journal of Tissue Engineering Research, 2024 1-12.

[13] Zhao Na, He Sheng, Shi Linan. Effects of 40 Hz Rhythmic Stimulation on Alzheimer's Disease and Cognitive Function. Progress in Biochemistry and Biophysics, 2024, 1-15.

[14] Guo X, Sheng X. Drug discovery of PD-L1 inhibitor Atezolizumab// Wuhan Zhicheng Times Cultural Development Co., Ltd.. Proceedings of 2nd International Conference on Biomedical Engineering, Healthcare and Disease Prevention (BEHDP 2022). The university of Strathclyde;The University of Melbourne, 2023: 8.

[15] Yu Haiyin, Li Xiaoning. Research Progress on Acupuncture Promoting Cell Proliferation and Differentiation after Spinal Cord Injury. Journal of Clinical Acupuncture, 2024, 40 (09): 96-101.

[16] Peng Jianhong, He Jiahua, Liao Leen, et al. Advances in the Clinical Application of Precision Medicine Testing in Hepatic Metastasis of Colorectal Cancer. Chinese ScienceBulletin, 2024, 1-11.

[17] Cao Xiaoshan, Yang Beibei, Cong Binbin, et al. Advances in the Treatment of Brain Metastases in Triple-Negative Breast Cancer. Chinese Journal of Cancer, 2024, 34 (08): 777-784.

[18] Xu Haoran, Zhao Xiaoyi, Nie He, et al. Immunotherapy for Colorectal Cancer. Progress in Biochemistry and Biophysics, 2024, 1-22.

[19] Liu Qing, Su Tingting, Gao Jiaming, et al. Effects of Tianshan Chaopiao on Adipogenic and Osteogenic Differentiation of Adipose-Derived Stem Cells. Journal of Tongji University (Medical Science), 2024, 45 (04): 471-479.
[20] Lin Meiyu, Zhao Xilong, Gao Jing, et al. Mechanisms and Progress of the Anti-Aging Effects of Stem Cells on Ovarian Granulosa Cells. Chinese Journal of Tissue Engineering Research, 2024, 1-8.
[21] Ying Yu-jia, Tang Yong-min. Analysis of Prognostic Factors and Progress in Treatment of Infant Acute Lymphoblastic Leukemia. Chinese Journal of Pediatric Hematology and Oncology, 2024, 29 (04): 299-302.
[22] Liu Qiang, Liu Hua-qian, Liu Li, et al. Current Status and Prospects of Mesenchymal Stem Cell-Targeted Therapy for Premature Ovarian Insufficiency. Chinese Journal of Cell Biology, 2024, 46 (08): 1567-1579.
[23] Wang Xin-xin, He Ji-hui, Li Gang, et al. Effects of Triclosan on Biological Characteristics of Dental Pulp Stem Cells. Prevention and Treatment of Oral Diseases, 2024, 1-15.
[24] Zheng Zi-ling, Li Yuanyuan, Shan Yuan-hong. Advances in Research on Genetic Doping and Its Detection Technologies// International Bandy Federation (FIB), International Strength and Conditioning Association (ISCA), Macao Strength and Conditioning Association (MSCA), Chinese Bandy Association (CBF). The Proceedings of the 2023 Inaugural International Sports Science Conference by the Chinese Radio Orienteering and Direction Finding Association (CRSOA). Shanghai University of Sport; Shanghai Anti-doping Laboratory, Shanghai University of Sport, 2023: 22.